Bayer, Amgen Unit Drop IP Suit Over Cancer Drug Generic
Bayer and Amgen's Onyx Pharmaceuticals on Thursday told a Delaware federal judge that they no longer wish to pursue patent litigation against Dr. Reddy's for attempting to bring a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article